EGFR and neoplasm: As, in most studies, EGFR expression and mutations were determined on the primary tumour, the observed clinical benefit of patients with wild-type EGFR or the absence of response to TKIs of patients with EGFR mutations could be due to discordance in the EGFR mutation status or expression between the primary tumour and the corresponding metastasis.